Normal
Meet the management team

ImmuPharma’s management team has substantial experience in the international pharma industry. It includes experienced executives and prominent scientists who provide expertise and contacts in the industry and the financial markets.

Richard Warr, MA
Chairman

Richard Warr has over 20 years’ experience in investment banking and corporate and government equity capital market transactions and was the architect of a large AIM flotation in 2004. Prior to co-founding ImmuPharma, he held positions as a director at ABN Amro Equities, head of European sales and marketing at Credit Lyonnais, executive director of Dresdner Kleinwort Benson and head of European equity distribution at Swiss Bank Corporation. He is a graduate of Oxford University.

Dr Franco Di Muzio
Senior Non-Executive Director

Dr. Di Muzio has 40 years experience in the pharmaceutical and other industries, encompassing international management experience in business development, strategic marketing, international finance, M & A and re-engineering businesses. After graduating in Economics and Business in 1963, Dr Di Muzio worked for Colgate Palmolive and Nestle before joining Squibb (now Bristol Myers Squibb) for eight years. Dr Di Muzio became Executive Vice President of BMS' medical equipment and products division, Weck International Inc., in charge of Europe, Asia, Middle East and Africa. In 1990, he joined Glaxo Wellcome plc. (now GlaxoSmithKline plc) in London as Area Managing Director and Head of all GW's business in the Middle East, Africa and Turkey. Following early retirement from Glaxo Wellcome, in the beginning of 1998, he joined Alza International, the then world leader in drug delivery systems, as Managing Director, based in London, in charge of the company's business expansion in all markets outside the US and remained there until the end of 2000.

Dimitri F Dimitriou, MSc
Chief Executive Officer

Dimitri F. Dimitriou has 25 years’ experience in the pharmaceutical and biotech industry. Prior to co-founding ImmuPharma, he was Senior Director, Worldwide Business Development at GlaxoSmithKline, where his responsibilities included worldwide corporate deals with pharmaceutical and biotech companies. He held a similar role in Europe for Bristol-Myers Squibb. He spent 8 years at Procter & Gamble in senior marketing, R&D and business development positions and began his career in marketing at Novartis (Sandoz) in 1987. He has a degree in biochemistry from Kings College, University of London and an MSc in pathology and toxicology from the Imperial College Medical School.

Dr Ajay Agrawal, PhD
Non-Executive Director

Dr Agrawal has 20 years’ experience in the biotech and pharmaceutical industry worldwide. He was a founder of polyMASC Pharmaceuticals plc, London in 1995, the first UK biotech company, derived from a university that was directly listed on AIM, raising approximately $40 million in 1995, and subsequently merged with a NASDAQ-listed company, Valentis Inc (USA) in 1999 to become one of the biggest companies in the delivery of biologics at that time. He currently sits on the editorial advisory board of three international medical journals, Current Drug Delivery, Infectious Disorders- Drug Targets, and Recent Patents on Drug Delivery and Formulation, Bentham Press, California, USA. Dr Agrawal has been a consultant to a number of companies in the sector, including Genovac GmbH (Germany), Qiagen (Germany), PHT Pharma (Italy) and Karo Bio (Sweden). He holds a PhD in Chemistry and has conducted his post-doctoral research in the faculty of Medicine, University of Alberta, Canada and at the Royal Free Hospital in London.

Dr Robert Zimmer, MD, PhD
President & Chief Science Officer

Dr. Robert Zimmer was the founder and chief executive officer of both ImmuPharma Switzerland and ImmuPharma France. He is an expert in clinical pharmacology and life cycle management. He was instrumental in developing a substantial number of products for clients including Roche, GlaxoSmithKline, Abbott, Searle, Sanofi-Aventis and Lilly. He began his career in Roche’s headquarters in Basle as coordinator of clinical pharmacology and international clinical leader. He subsequently joined Jago Pharma, the drug delivery company, and became a director and head of research and development at SkyePharma after it acquired JAGO. He obtained his MD at Strasbourg Medical School and his PHD at the University of Aix-Marseille.

Dr Paolo Bessieres
Vice President, Business Development

Dr. Paolo Bessieres has been involved in numerous collaboration projects over the past 20 years and has finalised over 20 deals. His experience includes partnerships for products and the creation of joint ventures and overseeing the alliance management. Dr Bessieres is also the CEO of PharmaWave Ltd, a company specialising in corporate partnerships in the life sciences. Prior to this, Dr Bessieres was Licensing Director at Sigma Tau, the second largest Italian pharmaceutical company. Dr Bessieres received his honours degree in Pharmacy in 1973 at the University of Rome, has been a member of many professional organisations as well as a speaker in international conferences.

Tracy Weimar
Vice President, Operations & Finance

Ms Weimar has spent over 8 years at GlaxoSmithKline and her most recent position there was Director, Worldwide Business Development where she was involved in a number of corporate licensing deals. She has also held a number of positions in health economics, strategy development, sales and marketing.

Ms Weimar was been a non-executive director for the Avon and Wiltshire Mental Health Partnership NHS Trust responsible for ensuring the Trust was accountable to the public for the services it provided and for the public funds it used. She was a member of both the Audit and Remuneration Committees of the Trust.

Prior to joining GlaxoSmithKline, Ms Weimar spent 5 years at Arthur Andersen in San Francisco and London, responsible for a range of consulting and compliance projects.

Ms Weimar holds an MBA from the London Business School and a BA in Economics from the University of California, Berkeley.

Lisa Baderoon
Head of Investor Relations

Lisa Baderoon has spent over 20 years working within the City of London and has been involved with a diverse portfolio of clients from a variety of sectors but with a leaning towards emerging, high growth businesses advising both private and public companies on their media and investor relations strategies. During this time she has been involved in a multitude of client transactions spanning private fund raisings, Initial Public Offerings (IPO’s) and mergers and acquisitions both in the UK and internationally.

Until December 2011 she was a Partner at Buchanan Communications, one of the leading City financial public relations agencies, where she was instrumental in establishing its successful healthcare franchise. Her client responsibilities included developing impactful IR strategies in addition to excellence in message development and managing relationships with media, the investment community and sell side analysts in Europe. She also has significant issue and crisis management experience from both an investor and media perspective.

Over the last six years she has been advising ImmuPharma as a client on its media and investor relations strategy and in February 2012 was appointed Head of Investor Relations at the Company. Lisa has also recently founded Just B Communications, a consultancy which specialises in helping businesses develop effective communications and through her network of blue-chip London City contacts providing access to a number of sources of corporate and investor development opportunities.

Richard Warr, MA
Chairman
Dr Franco Di Muzio
Senior Non-Executive Director
Dimitri F Dimitriou, MSc
Chief Executive Officer
Dr Ajay Agrawal, PhD
Non-Executive Director
Dr Robert Zimmer, MD, PhD
President & Chief Science
Officer
Dr Paolo Bessieres
Vice President, Business
Development
Tracy Weimar
Vice President, Operations & Finance
Lisa Baderoon
Head of Investor Relations